A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

NCT07172802 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor
Non-small Cell Lung Cancer (NSCLC)
Head and Neck (HNSCC)
Pancreatic Cancer
Renal Cell Carcinoma (RCC)

Interventions

DRUG: GI-108

Sponsor

GI Innovation, Inc.